Clindabone®

Oral tablet.

Oral antibiotic.

Clindamycin is an antibiotic belonging to the group of Lincosamides, which corresponds to a semi-synthetic modification of Lincomycin. It has a spectrum of action similar to Erythromycin, i.e. gram-positive bacteria, especially Staphylococci, Streptococci and anaerobic bacteria. Lincosamides are useful for the treatment of Penicillin, Erythromycin, and Cephalosporin-resistant infections.
Clindmycin inhibits bacterial protein synthesis, altering translocation. It binds to the 50S subunit of the bacterial ribosome, preventing the translocation of transfer RNA from the A site to the P site of the ribosome, preventing the formation of peptide bonds and generating inhibition of the protein synthesis of the microorganism.

Each 620 mg tablet contains:
Clindamycin Hydrochloride………….. 195.04 mg
(Equivalent to 165 mg clindamycin base)
Excipients c.s.p………………………….. 620 mg

Indicated for the treatment of infections caused by clindamycin-sensitive bacteria, such as Staphylococcus, Streptococcus, and anaerobic bacteria such as Bacteroides spp., Fusobacterium spp., Peptostreptococcus spp., Clostridium perfringens and many species of Propionibacterium spp. It also exhibits activity against Toxoplasma gondii.
Its use is indicated for the treatment of infections caused by clindamycin-sensitive bacteria in dogs and cats. In dogs, its use is recommended as the therapy of choice for the treatment of oral infections, pyoderma and osteomyelitis. In cats, its use is especially recommended for the treatment of oral infections. Clindamycin is also indicated in cases of toxoplasmosis in dogs and cats, as it improves the clinical signs associated with active infection with Toxoplasma gondii.

Dogs and cats.

Oral administration.

The recommended dose in dogs and cats for the treatment of oral infections is 11 mg/kg every 24 hours or 5.5 mg/kg body weight every 12 hours, for 5 days. For the treatment of osteomyelitis in dogs, a dose of 11 mg/kg body weight every 12 hours for 28 days is recommended. The recommended dose for the treatment of pyoderma in dogs is 11 mg/kg every 24 hours or 5.5 mg/kg body weight every 12 hours, for a minimum of 21 consecutive days or for at least 7 days after apparent clinical cure. For the treatment of toxoplasmosis, a dose of clindamycin for dogs and cats of 10 to 40 mg/kg and 25 to 50 mg/kg, respectively, divided into 2 daily doses, for 14 to 21 days, is recommended.

Oral administration.

Active ingredient dose:

The recommended dose for dogs and cats for the treatment of oral infections is: 11 mg/Kg of weight every  24 hours or 5.5 mg/Kg of weight every 12 hours, for 5 days. For the treatment of osteomyelitis in dogs is recommended a dose of 11 mg/Kg of weight every 12 hours, for 28 days. The beginning active dose for the treatment of pyoderma in dogs is 11mg/Kg every 24 hours or 5.5 mg/Kg of weight every 12 hours, for a minimum of 21 consecutive days or at least 7 days after the apparent clinical cure. For the treatment of toxoplasmosis is recommended a dose of Clindamycin for dogs and cats of 10 to 40 mg/Kg and 25 to 50 mg/Kg, respectively, divided into 2 daily doses, for 14 to 21 days.

Product dose:

OraI infections  (Periodontitis):

• Dogs: ½ Tablet for every 15 Kg of weight twice a day, or 1 tablet for every 15 Kg of weight, once a day for 5 days
• Cats: ¼ Tablet for every 4 kg of weight, once a day for 5 days. 

Osteomyelitis:

• Dogs: 1 tablet for every 15 Kg of weight, twice a day for 28 days.

Pyoderma:

• Dogs: ½ Tablet for every 15 Kg of weight, twice a day or 1 tablet for every 15 Kg of weight, once a day for 21 consecutive days or at least 7 days after the apparent clinical cure.   

Toxoplasmosis:

• Dogs: 1 tablet for every 10 Kg of weight, twice a day, for 14 to 21 days.
• Cats: ¼ Tablet for every 2 to 3 Kg of weight, twice a day, for 14 to 21 days.

• Do not administer in animals with hypersensitivity to lincomycin and clindamycin.
• Do not use on newborn puppies or kittens.
• Do not administer to cats weighing less than 2 kg.
• Do not administer concomitantly with other antibiotics such as chloramphenicol or macrolides.
• Do not use on species other than those indicated as its ingestion can cause serious gastrointestinal disorders.

Long-term use of clindamycin may occasionally cause anorexia, vomiting, and diarrhea.

• Keep out of reach of children.
• In prolonged therapy, the use of probiotics is recommended to maintain the balance of the normal intestinal flora.
• Use with caution in dehydrated or hypovolemic animals due to risk of renal toxicity.
• In case of prolonged treatments with clindamycin, periodic tests of liver function, kidney function and blood count should be performed.

Do not administer to pregnant or lactating females.

• Lincosamides have a neuromuscular additive effect, when applied with anesthetic agents and skeletal muscle relaxants.
• The association with Kaolin-Pectin does not allow absorption from the gastrointestinal tract.
• It should not be combined with other bactericidal agents, nor with macrolides, as antagonisms or nephrotoxicity may exist.
• Cyclosporines: Clindamycin can reduce levels.
• Erythromycin: antagonism in vitro when administered with clindamycin.

Not applicable.

• Wash your hands after administering the product.
• In case of accidental ingestion, do not induce vomiting, it is recommended to seek immediate medical attention.
• In case of contact with eyes, rinse with plenty of water for at least 15 minutes. In the event of any type of irritation, it is recommended to go to the doctor.
• If there is any type of skin irritation, it is recommended to see a doctor.

Dispose of unused product residues in their original packaging. Do not dispose of the empty container or with product residues in rivers, lakes or natural water streams. Dispose of waste of this product with caution along with household waste.

Store at a temperature between 15 and 30°C, away from light.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG No. 1959-B
Uruguay: Reg. MGAP N° 2018A00613
Peru: Reg. SENASA F.82.21.I.0448
Bolivia: Reg. SENASAG PUV-N° 009902/21

Box with 20 tablets.

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.